Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2012 December;60(6) > Minerva Cardioangiologica 2012 December;60(6):637-41

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695


eTOC

 

CASE REPORTS  


Minerva Cardioangiologica 2012 December;60(6):637-41

Copyright © 2012 EDIZIONI MINERVA MEDICA

language: English

Ventricular tachycardia in “end stage” hypertrophic cardiomyopathy: a role of dronedarone

Nanda S., Levin V., Martinez M. W.

Division of Cardiovascular Medicine, Lehigh Valley Health Network, Allentown, PA, USA


PDF  


Hypertrophic cardiomyopathy (HCM) occurs in 1 in every 500 individuals. It represents the most common cause of sudden cardiac death in those under the age of twenty-five. 3-5% patients with HCM go on to develop the dilated, hypokinetic end stage (ES) HCM with systolic failure. They have a higher incidence of heart failure, sudden deaths and defibrillator shocks. To the best of our knowledge this is first report of successful use of dronedarone for suppression of VT associated with ES HCM.

top of page

Publication History

Cite this article as

Corresponding author e-mail

Matthew_W.Martinez@lvhn.org